{"nctId":"NCT00769886","briefTitle":"Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.","startDateStruct":{"date":"2008-10"},"conditions":["Allergic Conjunctivitis"],"count":144,"armGroups":[{"label":"KetoNaph","type":"EXPERIMENTAL","interventionNames":["Drug: Ketotifen/naphazoline"]},{"label":"Naphazoline","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Naphazoline"]},{"label":"Ketotifen","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ketotifen"]},{"label":"Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle"]}],"interventions":[{"name":"Ketotifen/naphazoline","otherNames":[]},{"name":"Ketotifen","otherNames":[]},{"name":"Naphazoline","otherNames":[]},{"name":"Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Positive history of ocular allergies and positive skin test reaction to cat hair, cat dander, grasses, ragweed, and/or trees within the past 24 months.\n* Calculated best-corrected visual acuity of 0.7 logMAR or better in each eye as measured using the ETDRS chart.\n* Positive bilateral conjunctival allergen challenge(CAC)reaction within 10 minutes of instillation of the last titration of allergen at visit 1.\n* Positive bilateral CAC reaction in at least 2 out of 3 time points at visit 2.\n\nExclusion Criteria:\n\n* Known contraindications or sensitivities to the study medication or its components.\n* Any ocular condition that, in the opinion of the investigator, could affect the subjects safety or trial parameters.\n* Use of disallowed medications during the period indicated prior to study enrollment or during the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ocular Itching","description":"Ocular itching was evaluated by the participant at 3, 5, and 7 minutes post challenge. Assessments were made using a 0-4 numerical analog scale, allowing 0.5-unit increments (but disallowing 0.25-unit increments), where: 0.0 = None and 4.0 = Incapacitating itch with an irresistible urge to rub.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.835"},{"groupId":"OG001","value":"0.49","spread":"0.860"},{"groupId":"OG002","value":"1.87","spread":"0.932"},{"groupId":"OG003","value":"1.93","spread":"0.998"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","spread":"0.785"},{"groupId":"OG001","value":"0.69","spread":"0.923"},{"groupId":"OG002","value":"1.90","spread":"0.936"},{"groupId":"OG003","value":"2.17","spread":"0.885"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","spread":"0.856"},{"groupId":"OG001","value":"0.72","spread":"0.885"},{"groupId":"OG002","value":"1.75","spread":"0.971"},{"groupId":"OG003","value":"1.97","spread":"0.984"}]}]}]},{"type":"PRIMARY","title":"Conjunctival Hyperemia","description":"Conjunctival hyperemia was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were completed using a 0-4 numerical analog scale, allowing 0.5-unit increments, where: 0.0 = None and 4.0 = Extremely severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.13","spread":"0.872"},{"groupId":"OG001","value":"1.49","spread":"0.761"},{"groupId":"OG002","value":"1.62","spread":"0.860"},{"groupId":"OG003","value":"2.24","spread":"0.581"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.39","spread":"0.865"},{"groupId":"OG001","value":"1.89","spread":"0.712"},{"groupId":"OG002","value":"1.68","spread":"0.957"},{"groupId":"OG003","value":"2.33","spread":"0.551"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.26","spread":"0.818"},{"groupId":"OG001","value":"1.77","spread":"0.805"},{"groupId":"OG002","value":"1.53","spread":"0.959"},{"groupId":"OG003","value":"2.24","spread":"0.587"}]}]}]},{"type":"SECONDARY","title":"Ciliary Redness","description":"Ciliary hyperemia (redness) was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were made using a 0-4 scale, allowing 0.5- unit increments, with 0.0 = None and 4.0 = Extremely severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":"0.873"},{"groupId":"OG001","value":"1.39","spread":"0.774"},{"groupId":"OG002","value":"1.66","spread":"0.917"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.28","spread":"0.907"},{"groupId":"OG001","value":"1.79","spread":"0.791"},{"groupId":"OG002","value":"1.71","spread":"0.995"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":"0.854"},{"groupId":"OG001","value":"1.77","spread":"0.810"},{"groupId":"OG002","value":"1.58","spread":"1.032"}]}]}]},{"type":"SECONDARY","title":"Episcleral Redness","description":"Episcleral hyperemia (redness) was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were made using a 0-4 scale, allowing 0.5- unit increments, with 0.0 = None and 4.0 = Extremely severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.21","spread":"0.891"},{"groupId":"OG001","value":"1.52","spread":"0.749"},{"groupId":"OG002","value":"1.71","spread":"0.951"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.41","spread":"0.865"},{"groupId":"OG001","value":"1.87","spread":"0.732"},{"groupId":"OG002","value":"1.77","spread":"0.988"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.35","spread":"0.895"},{"groupId":"OG001","value":"1.88","spread":"0.777"},{"groupId":"OG002","value":"1.68","spread":"1.026"}]}]}]},{"type":"SECONDARY","title":"Chemosis","description":"Chemosis was evaluated by the Investigator at 7, 15, and 20 minutes post challenge on a 0-4 numerical analog scale, allowing 0.5-unit increments, where: 0.0 = None and 4.0 = Extremely severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"0.410"},{"groupId":"OG001","value":"0.22","spread":"0.313"},{"groupId":"OG002","value":"0.51","spread":"0.705"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"0.488"},{"groupId":"OG001","value":"0.42","spread":"0.420"},{"groupId":"OG002","value":"0.66","spread":"0.787"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":"0.549"},{"groupId":"OG001","value":"0.41","spread":"0.450"},{"groupId":"OG002","value":"0.66","spread":"0.869"}]}]}]},{"type":"SECONDARY","title":"Eyelid Swelling","description":"Lid swelling was evaluated by the subject at 7, 15, and 20 minutes post challenge on a 0- 3 numerical analog scale, with 0.5-unit increments disallowed, where: 0.0 = None and 3.0 = Severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.373"},{"groupId":"OG001","value":"0.32","spread":"0.604"},{"groupId":"OG002","value":"0.61","spread":"0.783"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.550"},{"groupId":"OG001","value":"0.37","spread":"0.638"},{"groupId":"OG002","value":"0.61","spread":"0.746"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":"0.581"},{"groupId":"OG001","value":"0.39","spread":"0.686"},{"groupId":"OG002","value":"0.59","spread":"0.729"}]}]}]},{"type":"SECONDARY","title":"Percentage of Eyes With Tearing","description":"Tearing was evaluated by the subject at 7, 15, and 20 minutes post challenge (absent or present). Tearing was recorded as either absent or present.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Eyes With Ocular Mucus Drainage","description":"Ocular mucous discharge was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Mucous discharged was recorded as either absent or present.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":36},"commonTop":[]}}}